Bovine Respiratory Disease (BRD) has an economic impact on cattle production, resulting in millions of dollars lost annually. Choosing an effective product is vital in minimizing the impact of BRD.
To portray drug-bug outcomes common in a clinical infection, current methods combine information from in vitro with in vivo studies. This tends to result in overestimated and underestimated measurements. A unique experimental live-animal model measures active (unbound) drug levels at the site of infection.